<unk>  has been proved to play a significant role in the pathophysiology of congestive heart failure (CHF).  Poor perfusion leads to activation of renin-angiotensin system which in turn elevates the levels of<unk> .<unk>  causes abnormal sodium retention in the body causing further progression of CHF. The RALES (Randomized Aldactone Evaluation Study) trial showed early reduction in morbidity and mortality using spironolactone, an<unk> <unk>  in combination with ACE inhibitors and loop diuretics in patients with congested heart failure.
Congestive heart failure aldosterone antagonists
Congestive heart failure calcium channel blockers
Congestive heart failure angiotensin receptor-neprilysin inhibitor
Congestive heart failure vasodilators
Congestive heart failure diuretics
Congestive heart failure Sodium-glucose co-transporter 2 inhibitors
Primary hyperaldosteronism medical therapy
Primary hyperaldosteronism surgery